Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Kim Koczka"'
Autor:
Kim Koczka, Rodrigo Rigo, Eugene Batuyong, Sara Cook, Mohammad Asad, Isabelle Vallerand, Aleksi Suo, Edwin Wang, Tina Cheng
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2427-2439 (2023)
Abstract Background Anti‐programmed death‐1 (PD‐1) immunotherapy has drastically improved survival for metastatic melanoma; however, 50% of patients have progression within 6 months despite treatment. In this study, we investigated host, and tu
Externí odkaz:
https://doaj.org/article/b6b0896f2221487c84ee846dcf3c4792
Autor:
Rodrigo Rigo, Jordan Doherty, Kim Koczka, Shiying Kong, Philip Q. Ding, Tina Cheng, Winson Y. Cheung, Jose G. Monzon
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 3978-3986 (2021)
Immune checkpoint and MAP kinase pathway inhibitors can significantly improve long-term survival for patients with melanoma. There is limited real-world data of these regimens’ effectiveness. We retrospectively analyzed 402 patients with unresectab
Externí odkaz:
https://doaj.org/article/1ed2b878f5f14461985de358d55e844e
Autor:
Kim Koczka, Rodrigo Rigo, Eugene Batuyong, Sara Cook, Mohammad Asad, Isabelle Vallerand, Aleksi Suo, Edwin Wang, Tina Cheng
Publikováno v:
Cancer Medicine. 12:2427-2439
Anti-programmed death-1 (PD-1) immunotherapy has drastically improved survival for metastatic melanoma; however, 50% of patients have progression within 6 months despite treatment. In this study, we investigated host, and tumor factors for metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80b661e59ace866dd872971d4f0a986b
https://doi.org/10.1002/cam4.5070
https://doi.org/10.1002/cam4.5070
Autor:
Jose Gerard Monzon, Winson Y. Cheung, Rodrigo Rigo, Kim Koczka, Shiying Kong, Philip Q. Ding, Tina Cheng, Jordan Doherty
Publikováno v:
Current Oncology
Volume 28
Issue 5
Pages 338-3986
Current Oncology, Vol 28, Iss 338, Pp 3978-3986 (2021)
Volume 28
Issue 5
Pages 338-3986
Current Oncology, Vol 28, Iss 338, Pp 3978-3986 (2021)
Immune checkpoint and MAP kinase pathway inhibitors can significantly improve long-term survival for patients with melanoma. There is limited real-world data of these regimens’ effectiveness. We retrospectively analyzed 402 patients with unresectab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe7364595b4da288de05ed95350622f6
Publikováno v:
Journal of Clinical Oncology. 39:e21531-e21531
e21531 Background: Anti-PD-1 immunotherapy has revolutionized metastatic melanoma treatment, as first-line monotherapy or in combination with Ipilimumab. Up to 40% of patients will progress within 3 months, with limited evidence on who derives benefi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1aef46919b18ee630e8770660c0499fb
https://doi.org/10.1200/jco.2021.39.15_suppl.e21531
https://doi.org/10.1200/jco.2021.39.15_suppl.e21531
Publikováno v:
Journal of Clinical Oncology. 38:e22013-e22013
e22013 Background: Adjuvant immunotherapies and adjuvant targeted therapy for melanoma became available in clinical practice in 2018 in Alberta, Canada. We describe the delivery of adjuvant systemic therapy, local-regional treatment, recurrence patte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32eaa8c6de6c628104f8ef76aae36d48
https://doi.org/10.1200/jco.2020.38.15_suppl.e22013
https://doi.org/10.1200/jco.2020.38.15_suppl.e22013
Autor:
Elham Sabri, Dominick Bossé, Michael Ong, Kim Koczka, Igal Kushnir, Christina Canil, M. Neil Reaume
Publikováno v:
Medical oncology (Northwood, London, England). 36(2)
Docetaxel pharmacokinetics are affected by androgen deprivation therapy (ADT), which is attributed to changes in liver metabolism induced by castration. In this retrospective analysis, we assessed whether initiating docetaxel treatment in close proxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4bd6b0145846f3002dadc8457843327
https://pubmed.ncbi.nlm.nih.gov/30666463
https://pubmed.ncbi.nlm.nih.gov/30666463
Autor:
Michael Ong, Christina Canil, Ranjeeta Mallick, Igal Kushnir, M. Neil Reaume, Kim Koczka, Dominick Bossé
Publikováno v:
Journal of Clinical Oncology. 37:e16501-e16501
e16501 Background: Several studies assessed the association of docetaxel dose intensity (DI) and efficacy in metastatic castrate-resistant prostate cancer (mCRPC) patients with contradicting conclusions. In this retrospective analysis we will assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1404c9e97053b2248eedde4553b8ec8
https://doi.org/10.1200/jco.2019.37.15_suppl.e16501
https://doi.org/10.1200/jco.2019.37.15_suppl.e16501
Autor:
Nedal Bukhari, Andrea Marie Ibrahim, Lori Sax, Michael M. Vickers, Christina Canil, Sandeep Sehdev, Kim Koczka, Kylea Potvin, Michael Ong, D. Scott Ernst, M. Neil Reaume, Eric Winquist, James Vanhie
Publikováno v:
Journal of Clinical Oncology. 36:193-193
193 Background: Outcomes of patients (pts) undergoing CHT for mHSPC are heterogeneous, with some rapidly developing castration-resistance (CRPC). While AVPC ("anaplastic") features are described in CRPC, less is known in the mHSPC setting. In this mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a2d8827f4644f188978bcab8620ecbb
https://doi.org/10.1200/jco.2018.36.6_suppl.193
https://doi.org/10.1200/jco.2018.36.6_suppl.193